I am the clinical operations director at a mid-size contract research organisation in Boston, in an office near the river where the rowing crews go out at an hour I am usually already at my desk. We run multi-country trials, which means that on any given morning I am holding the operational reality of a study that spans Massachusetts, several European countries, and a handful of sites in places where the assumptions I grew up with about banking simply do not apply. The science is rigorous. The protocols are exquisite. The monitoring is relentless. And for years, the single most embarrassing part of my operation, the part I would not have wanted a regulator or a participant to see up close, was how we paid the people who make the trials possible in the first place.

Participant payments were treated, across our industry and certainly in our shop, as a site-coordinator afterthought. Reimbursement for travel, a stipend for time, compensation for the burden of showing up to a clinic at seven in the morning to have blood drawn. We handled it the way it had always been handled: paper cheques, mostly, cut at the site, mailed to participants, including participants in rural areas for whom a mailed cheque is a genuine inconvenience and sometimes a small humiliation. In our international arms it was worse. There were FX surprises, where a participant received an amount that bore little resemblance to what we intended after conversion and fees. There were delays measured in weeks. And none of it appeared on the dashboards we actually watched, because we had filed it mentally under administration rather than operations.

The complication that forced my hand was not a complaint, though there were plenty of those. It was a pattern in the data that I could no longer pretend not to see. Dropout was correlating with payment friction. Participants at sites where reimbursement was slow or confusing were leaving studies at a higher rate, and in clinical research a participant who drops out is not just a service failure, it is a hole in your dataset and a threat to the integrity of the whole endeavour. The most rigorous trial in the world is undermined if the people in it leave because a cheque never came. I had been treating payments as the least scientific thing I managed. The data was telling me it was one of the most consequential.

So I went and read, properly, the way I would for any operational risk I had underweighted. The piece that reframed it for me was a guide to clinical trial participant payments that argues payout design should start as a product requirement rather than a late legal review, with ownership shared across product, finance, operations, and engineering from the beginning. It located the difficulty exactly where I had felt it without naming it, at the intersection of clinical-trial regulations, data-privacy regulations, and banking regulations, all colliding inside one program once it spans multiple countries. It was sharp on privacy in particular, that under GDPR health data is special-category data, and that payment operations tied to trial participation cannot simply assume ordinary consumer-payments handling is adequate. And it named the failure mode I was living: strong teams stall on payouts when ownership is split, when legal owns permissibility, finance owns controls, ops owns the participant experience, and engineering owns the data, and those decisions happen in sequence instead of together, producing rework and inconsistent country handling. That was a description of my organisation, written by someone who had clearly seen it before.

The hardest sites were the ones where participants are unbanked, and I had no framework for them beyond improvisation. What gave me one was a guide on paying unbanked contractors in developing markets that insists you choose payout routes by recipient fit, failure recovery, and compliance alignment rather than by whichever rail is easiest to integrate. It was written for platforms paying contractors, not for trials, but the thinking mapped onto my problem almost perfectly. The recipients differ; the payout-route logic does not. It walked through bank transfers, mobile wallets, cash pickup, and other routes as a layered toolkit rather than a single answer, and it was firm that most teams need more than one method, with clear evidence and reconciliation and a phased rollout rather than a flag-day switch. The line I underlined, mentally, was that treating the payout choice as a narrow vendor-selection exercise pushes you toward whatever is easiest to demo, and produces a system that works for a subset of recipients and grows fragile the moment circumstances vary by country. That was every well-intentioned shortcut my sites had ever taken.

What I settled on, and what we are now rolling out study by study, is to treat participant payments as global payout infrastructure rather than a coordinator's clerical duty. We define payment terms early and classify each payout as reimbursement, compensation, or both, because the classification drives the tax and privacy handling and cannot be retrofitted. We set minimum data, approval, privacy, and reconciliation controls up front, and we choose centralised, local, or hybrid routing per country based on its actual risk profile rather than a default. We offer routes that fit the participant, including for those without a bank account, instead of defaulting everyone to a cheque. And we pause expansion into a new country when classification, reconciliation, or privacy issues keep recurring, the same way we would pause for a safety signal. I am an operations director, not counsel, and the privacy and tax determinations sit with people qualified to make them; what I own is the infrastructure that lets them.

I still think about the cheque sitting in a rural mailbox, the participant who waited weeks for an amount that did not quite add up, the quiet way she stopped answering the coordinator's calls. She was a data point leaving my study, and she was also a person we had treated carelessly at the one moment we asked the most of her. The science was never the part we were getting wrong. The plumbing was. The crews are still out on the river when I get in. The payments, at last, are something I am no longer ashamed to explain.